Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible

    NEXT STORY
    Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet™ bionic pancreas using dasiglucagion
    PREV STORY
    Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

    author_avatar
    NASDAQ Market News

    Inivata Achieves Major Milestone with Draft Medicare Local Coverage Determination (LCD) for InVisionFirst™-Lung Liquid Biopsy Test

    Inivata Achieves Major Milestone with Draft Medicare Local Coverage Determination (LCD) for InVisionFirst™-Lung Liquid ...

    author_avatar
    NASDAQ Market News

    Genmab Announces Data to be Presented at 2018 ASCO Annual Meeting

    author_avatar
    NASDAQ Market News